[VIRTUAL] Patterns of response to atezolizumab (atezo) + bevacizumab (bev) in hepatocellular carcinoma (HCC) from the Phase 1b GO30140 study

[VIRTUAL] Characteristics of patients who received regorafenib for unresectable hepatocellular carcinoma in routine clinical practice: interim analysis of the prospective, observational REFINE study

[VIRTUAL] Outcomes based on albumin-bilirubin grade in the phase 3 RESORCE trial of regorafenib versus placebo in patients with advanced hepatocellular carcinoma

[VIRTUAL] A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL.

[VIRTUAL] Phase 1 study of autologous hepatitis B virus (HBV)-specific T cell receptor (TCR) T-cells, LioCyx-M in unresectable HBV-related hepatocellular carcinoma (HCC)

[VIRTUAL] Phase 3 KEYNOTE-937 Trial: Adjuvant Pembrolizumab for Hepatocellular Carcinoma and Complete Radiologic Response After Surgical Resection or Local Ablation

[VIRTUAL] Is first- and second-line immunotherapy sequence the optimal strategy for unresectable hepatocellular carcinoma?

[VIRTUAL] A phase II study of stereotactic body radiotherapy (SBRT) combined with sintilimab in patients with oligometastases of hepatocellular carcinoma (HCC)

[VIRTUAL] IMbrave150: updated overall survival (OS) data from a global, randomized, open-label Phase III study of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)

[VIRTUAL] Efficacy and safety of pemigatinib in European patients with previously treated locally advanced or metastatic cholangiocarcinoma: a FIGHT-202 subgroup analysis